Doctor-prescribed peptides, shipped to your door.

Lithium interaction and mood-treatment safety guide

Methylene blue and lithium: interaction and serotonin-syndrome questions

Review methylene blue with lithium using current label warnings, route-specific serotonin risk, lithium-toxicity monitoring, bipolar-care continuity, G6PD questions, and pharmacy checks.

Educational guideUpdated July 31, 2026

A safer lithium and methylene-blue review path

1

Identify the exact lithium and methylene-blue products: prescription lithium salt and formulation, oral or injected methylene blue, concentration, prescriber, pharmacy, directions, and recent changes.

2

Protect continuity of mood care. Clarify what lithium is treating, how stable mood and sleep are, when the latest serum lithium and kidney tests were done, and which clinician owns the plan.

3

Disclose every serotonin-related exposure, including SSRIs, SNRIs, MAOIs, tricyclics, buspirone, trazodone, migraine medicines, opioids, dextromethorphan, linezolid, stimulants, tryptophan, St. John’s wort, and supplements.

4

Review dehydration, vomiting, diarrhea, fever, major sodium changes, kidney or thyroid disease, NSAIDs, diuretics, blood-pressure medicines, G6PD status, pregnancy context, and planned procedures.

5

Reject research-use or dye-grade methylene blue, no-prescription lithium, lithium-orotate substitution claims, copied washout charts, and sellers that hide the clinician or dispensing pharmacy.

Direct answer

Do not combine methylene blue with prescription lithium, or stop, skip, reduce, or restart lithium to try oral methylene blue, without coordinated review by the lithium prescriber and a pharmacist. Current lithium labeling warns that combining lithium with serotonergic drugs can precipitate serotonin syndrome. Current PROVAYBLUE injection labeling says methylene blue is a potent reversible monoamine oxidase inhibitor and warns about serious or fatal serotonin syndrome with serotonergic medicines. The approved PROVAYBLUE warning is based on intravenous methylene blue and does not establish a safe compounded-oral dose, timing interval, or do-it-yourself washout plan. Lithium also has a narrow safety range and requires serum-level, kidney, thyroid, hydration, and medication monitoring; methylene-blue interest should not interrupt that care.

Different treatment roles

Prescription lithium is a mood stabilizer; oral methylene blue is not a substitute

Current lithium carbonate labeling identifies lithium as a mood-stabilizing medicine for acute manic or mixed episodes and maintenance treatment in bipolar I disorder. FDA-approved methylene-blue injections treat acquired methemoglobinemia. Low-dose oral methylene blue marketed for focus, energy, mood, mitochondrial support, or longevity is a different route and an off-label or compounded pathway—not an FDA-approved treatment for bipolar disorder and not a lithium replacement.

  • Do not replace, pause, reduce, or restart lithium because a post calls methylene blue a nootropic, natural mood stabilizer, antidepressant, or faster cognitive option.
  • New insomnia, agitation, depression, racing thoughts, impulsivity, confusion, tremor, fatigue, or concentration changes can reflect a mood episode, lithium toxicity, another medicine, sleep loss, substance use, infection, dehydration, or another issue requiring evaluation.
  • Record the exact lithium formulation, treatment goal, schedule, recent serum level, kidney and thyroid monitoring, adherence, response, side effects, and responsible clinician before discussing methylene blue.

Serotonin and route boundary

The current labels create a stop-and-review signal—not a home washout schedule

Current lithium labeling warns that concomitant serotonergic drugs can precipitate serotonin syndrome and calls for monitoring. Current PROVAYBLUE labeling explains that methylene blue can inhibit monoamine oxidase and warns that combining intravenous PROVAYBLUE with serotonergic medicines has caused serious or fatal serotonin syndrome. The approved labels do not provide a patient-directed method for combining lithium with compounded oral methylene blue, nor do they prove that a low-dose oral product avoids the interaction concern.

  • Do not assume a low oral dose, dropper, capsule, gummy, compounded route, different color, or seller’s “microdose” makes concurrent lithium use safe.
  • Do not convert intravenous-label timing language into instructions for stopping, starting, reducing, or restarting lithium or oral methylene blue; lithium changes require individualized prescriber monitoring.
  • Possible serotonin-syndrome features include agitation, confusion, hallucinations, sweating, fever, diarrhea, tremor, muscle rigidity, overactive reflexes, fast heart rate, seizures, or unstable blood pressure; severe or rapidly worsening symptoms require urgent care.

Lithium-specific safety

Serum levels, hydration, kidneys, sodium, thyroid, and interacting medicines still matter

Lithium labeling carries a boxed warning because toxic concentrations are close to the therapeutic range. Toxicity can involve worsening tremor, weakness, lack of coordination, drowsiness, confusion, slurred speech, vomiting, diarrhea, seizures, coma, kidney problems, or cardiac changes. Dehydration, fever, vomiting, diarrhea, kidney impairment, and major sodium changes can increase risk. NSAIDs, diuretics, renin-angiotensin-system medicines, metronidazole, and other drugs may alter lithium exposure or monitoring needs. These are separate from the serotonin interaction concern and should not be blurred into a claim that methylene blue necessarily raises the lithium level.

  • Share recent serum lithium, kidney, thyroid, calcium, electrolyte, hydration, and medication information with the lithium prescriber; do not change salt, fluid intake, or lithium dosing from an online interaction page.
  • Review ibuprofen or other NSAIDs, diuretics, ACE inhibitors, ARBs, metronidazole, antipsychotics, serotonergic medicines, supplements, alcohol, cannabis, heat exposure, illness, and any recent diet or fluid change.
  • Seek urgent medical evaluation for severe confusion, marked unsteadiness, slurred speech, repeated vomiting or diarrhea, seizure, fainting, dangerous agitation, high fever, severe rigidity, or rapidly worsening symptoms.

Methylene-blue safety and sourcing

G6PD status, product identity, and pharmacy accountability remain essential

Current methylene-blue injection labeling separately addresses G6PD-related hemolytic anemia, hypersensitivity, serotonin syndrome, kidney impairment, and neurologic or visual effects. It does not approve low-dose oral methylene blue for bipolar disorder, depression, ADHD, focus, fatigue, or lithium replacement. Compounded preparations are not FDA-approved finished drug products. Search results can mix prescription lithium with lithium-orotate supplements and licensed care with aquarium dye, research chemicals, vague “pharmaceutical grade” liquids, copied stacks, and sellers that omit medication screening.

  • Review known or possible G6PD deficiency, anemia or hemolysis, dark urine or jaundice, pregnancy or breastfeeding, kidney or liver disease, dye reactions, exact route and concentration, and the dispensing pharmacy.
  • Tell surgeons, anesthesiology teams, emergency clinicians, and procedural staff about lithium and any oral, injected, research-use, or supplement-marketed methylene blue before a procedure or acute treatment.
  • Avoid aquarium, laboratory, industrial, dye-grade, or research-use methylene blue and any seller that bypasses prescription review, mood screening, serum-level monitoring, interaction checks, or urgent follow-up.

Patient safety checklist

Questions to ask before considering methylene blue with lithium

These points are educational and do not replace medical advice. A licensed clinician should review individual history, medications, risks, and state-specific availability before treatment.

✓

What is lithium treating, how stable are mood and sleep, and which psychiatrist or other clinician owns the treatment plan?

✓

Which exact lithium salt, formulation, schedule, pharmacy, prescriber, serum level, recent changes, and last-use details apply?

✓

Which exact methylene-blue product, route, concentration, label, pharmacy, intended use, and prescriber apply?

✓

Has the lithium prescriber reviewed methylene blue’s reversible-MAOI and serotonin warning with a pharmacist instead of relying on a seller interaction checker or washout chart?

✓

Have I disclosed every antidepressant, opioid, migraine medicine, cough product, linezolid, buspirone, trazodone, stimulant, sleep medicine, alcohol or substance exposure, and serotonin-related supplement?

✓

Are serum lithium, kidney function, thyroid function, calcium, electrolytes, hydration, illness, vomiting, diarrhea, fever, and recent sodium or fluid changes current?

✓

Have NSAIDs, diuretics, ACE inhibitors, ARBs, metronidazole, antipsychotics, and other medicines that can affect lithium safety been reviewed?

✓

Do G6PD deficiency, anemia or hemolysis history, pregnancy context, kidney or liver disease, or a prior dye reaction change the methylene-blue discussion?

✓

Is the oral methylene blue a patient-specific prescription from an identifiable licensed pharmacy, or a research-use, dye-grade, imported, gummy, or no-prescription product?

✓

What mood follow-up, serum-level plan, urgent-care threshold, and clinician contact plan apply before any decision about either product?

FAQs

Short answers for patients

Can I take methylene blue with lithium?

Do not combine them without coordinated review by the lithium prescriber and a pharmacist. Current lithium labeling warns that serotonergic drugs can precipitate serotonin syndrome, while current PROVAYBLUE labeling describes methylene blue as a potent reversible monoamine oxidase inhibitor and warns about serious or fatal serotonin syndrome with serotonergic medicines. The exact product, route, source, timing, serum lithium context, and full medication list matter.

Should I stop lithium before trying oral methylene blue?

Do not stop, skip, reduce, or restart lithium on your own. Approved intravenous-methylene-blue label language does not create a self-directed schedule for compounded oral methylene blue. Uncoordinated lithium changes can destabilize mood care and require serum-level monitoring; ask the prescriber and pharmacist whether methylene blue should be avoided.

Does a low-dose oral methylene-blue product avoid the warning?

The approved PROVAYBLUE warning is based on intravenous methylene blue, so route-specific evidence is limited. That limitation does not establish a safe oral dose, concentration, combination, or timing interval with lithium. Product-specific prescriber and pharmacist review is still necessary.

Can methylene blue replace lithium for bipolar disorder?

No FDA label supports low-dose oral methylene blue as a lithium replacement for bipolar I disorder. FDA-approved methylene-blue injections treat acquired methemoglobinemia. Do not change a clinician-managed mood plan because of nootropic, longevity, antidepressant, or “natural mood stabilizer” claims.

Is this mainly a lithium-level interaction?

The primary concern supported by the two labels is serotonin toxicity: lithium labeling warns about serotonergic drugs, and PROVAYBLUE labeling describes reversible MAO inhibition and serotonin syndrome. Lithium has additional level-related risks involving kidneys, hydration, sodium, illness, and interacting medicines, but this page does not claim methylene blue itself necessarily raises serum lithium.

What symptoms need urgent attention?

Severe confusion, dangerous agitation, high fever, marked rigidity, overactive reflexes, seizure, repeated vomiting or diarrhea, severe weakness, major unsteadiness, slurred speech, fainting, or rapidly worsening symptoms need urgent medical evaluation. Do not try to distinguish serotonin syndrome from lithium toxicity by taking another dose or following an online protocol.

Is lithium orotate the same as prescription lithium carbonate?

No. Product identity, salt, amount, quality controls, intended use, and medical monitoring differ. Do not substitute a lithium-orotate supplement for prescribed lithium or assume it removes interaction concerns. Disclose every lithium-containing product to the prescriber and pharmacist.

Sources and related reading

Peptide12 pages use conservative educational language and authoritative sources where possible.

DailyMed: Lithium carbonate capsules prescribing information — published July 2026openFDA: Current lithium carbonate label data, boxed warning, and serotonergic-drug interactionMedlinePlus: Lithium drug informationDailyMed: PROVAYBLUE (methylene blue) injection prescribing informationopenFDA: Current PROVAYBLUE boxed warning and drug-interaction label dataPubMed: Methylene blue is a potent monoamine oxidase inhibitorFDA: Compounding and the FDA — Questions and AnswersPeptide12: Methylene blue and buspironePeptide12: Methylene blue and trazodonePeptide12: Methylene blue and WellbutrinPeptide12: Methylene blue medication interactionsPeptide12: Methylene blue safety guidePeptide12: Mental-health history checklistPeptide12: When in-person care is neededPeptide12: Low-dose oral methylene bluePeptide12: How online peptide therapy works